💊 الأدوية من أ إلى ي 🧬 الأهداف 🛠 الأدوات 📚 الأدلة
جميع الأدوية تصنيفات الأدوية المجالات العلاجية الآثار الجانبية
الأدلة المسرد الجدول الزمني
المقارنات مسارات الأدوية عائلات الأدوية
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Sacituzumab Govitecan

CHEMBL3545262 Phase 4 معتمد Antibody drug conjugate
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
— g/mol
LogP
—
Phase
4

Sacituzumab govitecan is an antibody-drug conjugate (ADC) consisting of a humanized anti-Trop-2 antibody linked to SN-38, the active metabolite of irinotecan, a topoisomerase I inhibitor. It is approved for the treatment of metastatic triple-negative breast cancer and advanced urothelial (bladder) cancer that has progressed on prior therapy. The ADC delivers cytotoxic SN-38 directly to Trop-2-expressing tumor cells, achieving tumor-selective cytotoxicity.

المجالات العلاجية

Melanoma Ovarian Cancer Pancreatic Cancer Bladder Cancer Thyroid Cancer Non-Small Cell Lung Cancer Breast Cancer Prostate Cancer Colorectal Cancer

آلية العمل

As a monoclonal antibody, it binds with high specificity to its target antigen, modulating the immune response through mechanisms including receptor blockade, immune cell engagement, or targeted cytotoxicity.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

الآلية

As a monoclonal antibody, it binds with high specificity to its target antigen, modulating the immune response through mechanisms including receptor blockade, immune cell engagement, or targeted cytotoxicity.

HBD / HBA

- / -

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

الأسئلة الشائعة

Sacituzumab govitecan is an antibody-drug conjugate (ADC) consisting of a humanized anti-Trop-2 antibody linked to SN-38, the active metabolite of irinotecan, a topoisomerase I inhibitor. It is approved for the treatment of metastatic triple-negative breast cancer and advanced urothelial (bladder) cancer that has progressed on prior therapy. The ADC delivers cytotoxic SN-38 directly to Trop-2-expressing tumor cells, achieving tumor-selective cytotoxicity.

As a monoclonal antibody, it binds with high specificity to its target antigen, modulating the immune response through mechanisms including receptor blockade, immune cell engagement, or targeted cytotoxicity.

Yes, Sacituzumab Govitecan is an approved drug. It has reached clinical phase 4. It is classified as a Antibody drug conjugate.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL3545262. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.

إخلاء المسؤولية الطبية

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.